Navigation Links
Silence Therapeutics Announces Board Changes and Appointment of New Chief Executive Officer
Date:2/10/2012

Thomas for his many years of valuable service to Silence and wish him well with his future endeavours. I am delighted that Tony has agreed to take on the CEO role. He has impressed us since joining and I am sure he will continue to do so."

Tony Sedgwick, newly promoted Chief Executive Officer, added: "Since joining Silence Therapeutics in September 2011, I have been excited by the Company and the opportunities that lie ahead.   We have a unique proprietary position in RNAi therapeutics and their delivery. I am confident that this will be further strengthened and will be the basis upon which investors and pharmaceutical partners alike will take an increasing interest in this Company. We have already strengthened the business development team with the appointment of Dr Georg Buchner who will now take full responsibility for business development. The Company's pipeline including  Atu027  is making good progress and is endorsed by external partners. I look forward to taking on the role of Chief Executive Officer and working with the staff at Silence to strengthen the Company's pipeline. Over the next few years, I intend to increase the commercial focus of the Company, harness the  RNAi therapeutics  opportunity and, as a result, create substantial'/>"/>

SOURCE Silence Therapeutics Plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Silence Therapeutics Additional Listing
2. Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
3. Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office
4. Silence Therapeutics Provides Corporate and Development Update
5. Silence Therapeutics Signs Collaboration With Mirna Therapeutics to Evaluate Delivery of Novel microRNA Therapeutics
6. Silence Therapeutics Issued Japanese Patent Covering its Core RNA Interference (RNAi) Technology
7. Silence Therapeutics Lead RNA Interference Therapeutic Prevents Spread of Cancer to Lungs
8. Silence Therapeutics Receives Comprehensive Protection for RNAi Structural Modification Technology in Single European Patent
9. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
10. Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent
11. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... (PRWEB) October 01, 2014 What: ... software solutions driven by Semantic Web technology, today announced ... in Washington, D.C. , Smart Data solutions provide ... users to rapidly discover, understand, analyze and manage diverse ... Cambridge Semantics, will present on building a “life sciences ...
(Date:10/1/2014)... , Oct. 1, 2014  Spherix Incorporated ... the fostering and monetization of intellectual property, announced ... against VTech and Uniden in the U.S. District ... Texas has been rescheduled for November ... October 2, 2014.  The Court Order setting the ...
(Date:10/1/2014)... CA (PRWEB) September 30, 2014 ... user-friendly, cost-effective tools to address sales, training and ... has developed innovative mobile applications to turn ... outlining the agency’s latest customized mobile app creations, ... http://www.studiopmg.com/work . , In partnership with Toyota, StudioPMG ...
(Date:10/1/2014)... The U.S. Department of Labor has awarded a ... part of the Trade Adjustment Assistance Community College and ... the Department of Labor and Department of Education. , ... Perez and Secretary of Education Arne Duncan announced the ... nearly 270 colleges across the country. , The ...
Breaking Biology Technology:Cambridge Semantics to Present ‘A Useful Approach to Big Data’ at 2014 Big Data Leaders Forum 2Markman Hearing Date for VTech and Uniden Litigation Now Set for November 10, 2014 2Digital Agency Studio PMG Launches New Case Studies on Website 2U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 2U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 3U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 4
... 1, 2011 Elsevier, a world-leading provider ... today announced the availability of Elsevier Urban & ... the life and health sciences, on SciVerse ScienceDirect ... under the renowned German imprint Urban & Fischer, contain ...
... researchers at the University of Toronto have developed the ... This result enables a flexible form factor, not to ... which currently relies on rigid glass. The ... Nature Photonics . OLEDs provide high-contrast and ...
... Moore,s Law, hardly a law but undeniably a persistent trend, ... transistors that fit on a chip roughly doubles. It,s why ... players to movie cameras, from tablets to supercomputers grow ... expensive. Whether the trend can continue until it runs up ...
Cached Biology Technology:Elsevier Announces Availability of Urban & Fischer Journal Archives on SciVerse ScienceDirect 2University of Toronto researchers create world's most efficient flexible OLED on plastic 2A SHARP new microscope for the next generation of biochips 2A SHARP new microscope for the next generation of biochips 3A SHARP new microscope for the next generation of biochips 4
(Date:9/30/2014)... have in common? Unlike most eukaryotic multicellular organisms ... these organisms are all polyploid, meaning they have three ... 3 and 4 sets of chromosomes, respectively, and strawberries ... fact most plant species are polyploid. Polyploidy, or genome ... only recently, with the development of molecular tools, has ...
(Date:9/30/2014)... Ecker, a Salk professor and Howard Hughes Medical ... have been named recipients in the 2014 round ... (NIH) through the BRAIN (Brain Research through Advancing ... The grant, announced September 30, provides more than ... over three years. , The BRAIN Initiative, launched ...
(Date:9/30/2014)... of Medicine reports positive results of a phase ... subset of lung cancer marked by rearrangement of the ... with advanced non-small cell lung cancer testing positive for ... with 3 complete responses and 33 partial responses. Median ... disease to resume its growth after being slowed by ...
Breaking Biology News(10 mins):Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 2Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 3Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 4Salk scientists receive $3 million for BRAIN Initiative grant 2NEJM: Crizotinib effective in Phase 1 trial against ROS1 lung cancer 2
... pollution is costing each person in Europe around 130 - ... Nitrogen Assessment (ENA) is launched at a conference today in ... from 21 countries and 89 organizations, estimates that the annual ... - 280 billion (70 -320 billion), more than double the ...
... COLUMBUS, Ohio Stress not only sends the human immune ... the trillions of bacteria that work and thrive inside our ... important because those bacteria play a significant role in triggering ... prepared to quickly spring into action in the face of ...
... DETROIT For nearly two decades following the 1991 Gulf War, ... conflict: an unexplainable cluster of symptoms including but not limited ... 2008 that a scientific panel from the U.S. Department of ... served in the Gulf War were suffering from combinations of ...
Cached Biology News:Excessive nitrogen harms the economy and environment -- first Europe-wide assessment published 2Stress wrecks intestinal bacteria, could keep immune system on idle 2WSU receives DOD grant to determine common genetic link among Gulf War Illness patients 2
Goat polyclonal to JIK ( Abpromise for all tested applications). Antigen: Synthetic peptide: HKKDHVFIRDEAGHGD, corresponding to amino acids 396-411 of Human JIK. Entrez Gene ID: 51347 Swi...
Mouse monoclonal [SPM325] to Xanthine Oxidase, prediluted ( Abpromise for all tested applications). Antigen: C terminal 358 amino acid fragment of human xanthine oxidase. Entrez Gene ID: 749...
Rab1A...
Drugs and NO-drug Rat Anti-conjugated Acetyl Salicylic Acid Polyclonal Antibody...
Biology Products: